FY2018 EPS Estimates for China Biologic Products, Inc. Decreased by Jefferies Group (NASDAQ:CBPO)
China Biologic Products, Inc. (NASDAQ:CBPO) – Investment analysts at Jefferies Group cut their FY2018 earnings per share estimates for China Biologic Products in a research report issued on Thursday. Jefferies Group analyst J. Wong now expects that the biopharmaceutical company will post earnings of $5.78 per share for the year, down from their previous estimate of $5.88. Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for China Biologic Products’ FY2019 earnings at $6.87 EPS.
China Biologic Products (NASDAQ:CBPO) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.05. The business had revenue of $89.28 million for the quarter, compared to analyst estimates of $97.33 million. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The business’s quarterly revenue was down 2.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.26 EPS. ILLEGAL ACTIVITY NOTICE: “FY2018 EPS Estimates for China Biologic Products, Inc. Decreased by Jefferies Group (NASDAQ:CBPO)” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/07/fy2018-eps-estimates-for-china-biologic-products-inc-decreased-by-jefferies-group-nasdaqcbpo.html.
Several other brokerages have also commented on CBPO. Zacks Investment Research lowered shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Wednesday, April 26th. Goldman Sachs Group, Inc. (The) assumed coverage on shares of China Biologic Products in a research note on Tuesday, May 30th. They set a “neutral” rating on the stock. Finally, BidaskClub lowered shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Sunday, July 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. China Biologic Products currently has an average rating of “Hold” and a consensus price target of $132.00.
China Biologic Products (CBPO) opened at 97.04 on Monday. The company’s 50 day moving average is $105.95 and its 200 day moving average is $108.21. The firm has a market cap of $2.64 billion, a price-to-earnings ratio of 25.26 and a beta of 1.70. China Biologic Products has a 12-month low of $96.00 and a 12-month high of $137.38.
In related news, insider Zhijing Cbpo Liu sold 7,500 shares of the firm’s stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $116.49, for a total value of $873,675.00. Following the transaction, the insider now directly owns 10,969 shares in the company, valued at approximately $1,277,778.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.73% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of CBPO. BlackRock Inc. raised its position in China Biologic Products by 694.1% in the first quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock worth $151,007,000 after buying an additional 1,318,183 shares during the last quarter. FMR LLC raised its position in China Biologic Products by 27.5% in the first quarter. FMR LLC now owns 1,880,549 shares of the biopharmaceutical company’s stock worth $188,300,000 after buying an additional 406,105 shares during the last quarter. Hermes Investment Management Ltd. raised its position in China Biologic Products by 91.6% in the first quarter. Hermes Investment Management Ltd. now owns 631,224 shares of the biopharmaceutical company’s stock worth $63,204,000 after buying an additional 301,828 shares during the last quarter. Macquarie Group Ltd. purchased a new position in China Biologic Products during the first quarter worth about $27,324,000. Finally, Artisan Partners Limited Partnership raised its position in China Biologic Products by 103.2% in the first quarter. Artisan Partners Limited Partnership now owns 395,578 shares of the biopharmaceutical company’s stock worth $39,609,000 after buying an additional 200,868 shares during the last quarter. Institutional investors and hedge funds own 74.09% of the company’s stock.
China Biologic Products Company Profile
China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment.
Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.